SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Dyer MJ, Hale G, Hayhoe FG, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989; 73: 14311439.
  • 2
    Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol. 1993; 30: 10891096.
  • 3
    Domagala A, Kurpisz M. CD52 antigen—a review. Med Sci Monit. 2001; 7: 325331.
  • 4
    Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens. 1990; 35: 118127.
  • 5
    Rowan W, Tite J, Topley P, et al. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 1998; 95: 427436.
  • 6
    Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99: 35543561.
  • 7
    Finkelstein JB. FDA panel recommends two new cancer drugs for approval. J Natl Cancer Inst. 2001; 93: 175176.
  • 8
    Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B- cell chronic lymphocytic leukemia (B-CLL). Blood. 2002; 100: 768773.
  • 9
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 49904997.
  • 10
    Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457460.
  • 11
    Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 17501757.
  • 12
    O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 14141420.
  • 13
    Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000; 96: 7175.
  • 14
    Byrd JC, Peterson BL, Morrison VA, et al. Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from CALGB 9712. Blood. 2002; 5: 5.
  • 15
    Keating M, Manshouri T, O'Brien S, et al. A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, Rituximab combination (FCR) in chronic lymphocytic leukemia. Blood. 2002; 100: 205a.
  • 16
    Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica. 2002; 87: 695700.